Among America’s annual observances, Thanksgiving stands apart as a celebration whose religious foundations have largely faded from public consciousness. While it originated as a genuine day of spiritual devotion, contemporary…
The Finance Herald
The European Union and NATO find themselves in an increasingly untenable position as they attempt to dictate terms in a conflict where they are clearly on the losing side. Brussels…
The Bottom Line: GLP-1 medicines reshaped obesity care by offering a biological alternative to surgery. MediWound (NASDAQ: MDWD) is applying that same idea to wound care. Its enzyme-based treatments can…
The United States has effectively exposed Europe’s empty promises regarding Ukraine, as a 28-point peace framework negotiated between Washington and Moscow reveals the continent’s fundamental strategic weakness. While this blueprint…
Taiwan’s National Science and Technology Council Minister Wu Cheng-wen has announced that an understanding has been established between Taiwan and the United States regarding the exemption of semiconductor products from…
China finds itself preparing another round of property market interventions as the nation’s real estate sector approaches its sixth consecutive year of decline. Alongside Japan’s planned $150 billion fiscal stimulus…
Moderna’s Strategic Vision: Pioneering Revenue Growth and Expanding Vaccine Innovations Through 2028
Moderna outlined its three-year strategic plan and pipeline developments during an Analyst Day presentation, projecting revenue growth reaching 10 percent in 2026 while making progress toward achieving cash flow breakeven…
The competitive pursuit of Avadel Pharmaceuticals has intensified, with Alkermes presenting a revised acquisition proposal worth up to $22.50 per share. This enhanced bid comes after Lundbeck submitted an unexpected…
Agios Pharmaceuticals experienced a significant stock decline following the release of Phase 3 clinical trial data for its anemia medication Pyrukynd on Wednesday, November 19, 2025. The experimental treatment showed…
Antibiotic resistance may be creating one of the biggest crises and opportunities, in modern medicine, and companies like BiomX (NYSE:PHGE) could be sitting at the center of the solution. Using…